Eliquis Beats Xarelto in Bleeding Risk Trial

A significant clinical trial has provided crucial evidence regarding the safety profiles of two common blood-thinning medications. Researchers reported in the New England Journal of Medicine that Eliquis, chemically known as apixaban, demonstrated a substantially lower risk of dangerous bleeding events when compared to Xarelto (rivaroxaban).

The comparative trial enrolled 2,760 patients diagnosed with venous thrombosis, which involves blood clots in the veins, typically in the legs or lungs. After a standard three-month treatment course, the study found that 7.1% of participants taking Xarelto experienced clinically relevant bleeding. In contrast, only 3.3% of those treated with Eliquis encountered such bleeding episodes.

While the study suggests both anticoagulants are effective in preventing recurrent blood clots, researchers noted that the participant numbers were insufficient to definitively establish a difference in this regard. However, the findings strongly support Eliquis as a safer first-line option for minimizing bleeding risks without compromising clot prevention.

Experts acknowledged certain limitations, including the study's focus on primarily white patients with healthy organs and without cancer or obesity. Despite these factors, the trial is considered vital for informing treatment decisions in venous thromboembolism.